FeesSafety
Pluang+

JPMorgan predicts Bitcoin will outperform gold and US stocks with 10% annual returns over the next decade.

Market News
04 Nov 2026, 18:41 WIB
Zycrypto
View Source
Bullish
JPMorgan predicts Bitcoin will outperform gold and US stocks with 10% annual returns over the next decade.

JPMorgan Asset Management forecasts Bitcoin to deliver a 10% annualized return over the next 10 to 15 years, outperforming gold, US stocks, and bonds. Despite Bitcoin's high volatility, the bank sees it as a strong long-term investment, marking the first time Bitcoin is included in JPMorgan's 31-year market forecast. This shift signals growing acceptance of Bitcoin as a major asset class, even from previously skeptical Wall Street figures like JPMorgan's CEO Jamie Dimon. Investors may consider Bitcoin a viable alternative to traditional safe-haven assets going forward.

JPMorgan's projection of Bitcoin's 10% annual return over the next decade provides context for cryptocurrency market activity on Pluang. For readers following digital assets, here is Pluang's market snapshot as of Nov 04, 2026 23:32 WIB: out of 50 major cryptocurrencies, 47 rose and 2 fell today. Notable movers include LINK at Rp210.973 (+4.80%), ADA at Rp3.605 (+4.52%), and AVAX at Rp162.234 (+4.52%), with typical hold times ranging from 64 to 128 days and buy order activity dominating sell orders.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
54 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
54 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
54 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
54 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
54 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App